Skip to main content

Dr. George W. Carr, MD

Family Medicine (Family Medicine Physician)

  • Medicare participating

At a glance

Years since graduation
41
In the NPI registry since
2006
Medicare patients seen, 2024
363

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1985Medical school: University of Missouri, Columbia School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Family Medicine Physician primary
    MO license 36781

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Family Medicine per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
363
Services billed
11,179
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes622267
Insertion of needle into vein for collection of blood sample431251
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count302225
Established patient office or other outpatient visit, 20-29 minutes258219
Blood test, thyroid stimulating hormone (tsh)248219
Thyroxine (thyroid chemical), free245216
Blood test, basic group of blood chemicals (calcium, total)230172
Hemoglobin a1c level209132
Blood test, lipids (cholesterol and triglycerides)207180
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit199199

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 33 companies reported 189 payments worth $3,093 in total to this clinician.

By type
Food and Beverage$2,977
Education$116

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Aug 28, 2025Lundbeck LLC
Aug 28, 2025
Education
REXULTI · PSYCHIATRY · in-kind
$38.54
Oct 30, 2025Lundbeck LLC
Oct 30, 2025
Education
REXULTI · PSYCHIATRY · in-kind
$38.54
Dec 16, 2025Lundbeck LLC
Dec 16, 2025
Education
REXULTI · PSYCHIATRY · in-kind
$38.54

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Missouri →

Industry-funded research

Named as a principal investigator on 11 industry-funded studies in 2025, from 8 companies. The companies reported $266,053 in research payments for these studies, mostly to the institutions running them.

  • A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients
    Novartis Pharmaceuticals Corporation
  • A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
    AstraZeneca Pharmaceuticals LP
  • A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clini…
    AstraZeneca Pharmaceuticals LP
  • A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
    Boehringer Ingelheim Pharma GmbH & Co.kg
  • A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
    AstraZeneca UK Limited
  • A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
    AstraZeneca Pharmaceuticals LP
  • Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
    Alnylam Pharmaceuticals Inc.
  • A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)
    Alnylam Pharmaceuticals Inc.
  • A phase 1/2, randomized, observer-blinded, multi-country study to eval
    GlaxoSmithKline, LLC.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Family Medicine clinicians in Jefferson City

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 10, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1528032661. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.